BGI Research is dedicated to using the world class genomics platform to contribute to the public health. Relying on innovative integration of platforms to achieve major scientific breakthroughs in the basic research area and lead technology development, BGI Research has four major areas of focus: Personal genomics, Cancer, Reproductive health, and Molecular breeding.
BGI College focuses on innovative education and training for multidisciplinary talents in bioscience and bioindustry. Programs include joint education, external training (bioinformatics training, medical related training & genetic counselor training) and public education (popular science education & summer internship). More than 100 PhD students and 300 MSc students have been trained.
GigaScience is an open-access open-data journal for the publication of all types of biological studies that use or create large-scale data sets. With the goal of revolutionizing data accessibility, dissemination, organization, and use, GigaScience has a unique format that integrates article publication with the data-hosting and cloud-computing resources. In three years GigaDB has stored over 194 datasets and 36TB data.
BGI Genomics provides a wide range of commercial next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. BGI Genomics’ mission is to leverage its genomics expertise in order to advance life science research and to improve human health by providing high quality, affordable genomics powered health solutions for everybody.
MGI specialises in R&D and manufacturing of proprietary instrumentation, medical devices, ancillary consumables and biological reagents e.g. genetic sequencers, mass spectrometers, medical imaging systems, and comprehensive solutions for life science research and applications. With the vision to “enable effective and affordable healthcare solutions for all”, MGI strives to be a leading innovator in life science technologies.
FGI, BGI's subsidiary specialised in forensics, provides accurate and affordable DNA genotyping services, and standardises the procedures for applying relevant technologies in the fields of human DNA identification, plant and animal identification and forensics science. Based on advanced BGI sequencing platform and database. FGI also focuses on the R&D of new technologies in forensic genomics, forensic pathology, and forensics.
On September 9, 2019, BGI celebrated its 20th anniversary. We thank all of you for being an integral part of this extraordinary journey, 20 years of genomic discovery and technological innovation.
BGI published a proof-of-principle metagenomics study in Nature on March 4, 2010, using short read sequencing to catalog and characterize the microbial genes present in the human gut. The work was listed as “Insights of the Decade” by Science. The study continues to achieve significant advances. BGI established pan-genome association analysis technology in 2012 revolutionising the disease clinical research. In 2019 BGI published 1,520 reference genomes from cultivated human gut bacteria enabling functional microbiome analyses.
Seven papers on the findings of an international yeast chromosome consortium study that BGI is heavily involved in were published in Science as the cover story and a special feature in the 2017 March issue. This project enables BGI to establish a high throughput automated synthetic biological platform and synthesize the first eukaryote which starts a new era of synthetic biology.
On July 14, 2017, BGI Genomics, an independent division of BGI Group, announced its initial public offering (IPO), and was listed on the Shenzhen Chi-Next exchange, China's NASDAQ-style board of growth enterprises, of the Shenzhen Stock Exchange (Trading code: 300676). BGI’s vision is using genomics to benefit the mankind.
It cost US$3 billion over the course of 13 years to generate the first human genome sequence as part of the Human Genome Project back in 2003. 15 years later MGI, a subsidiary of BGI Group, introduced its newest model of genetic sequencer in October 2018, MGISEQ-T7, the most powerful next generation sequencer, taking production capacity of the instrument to a new level which can process 60 human genomes’ sequence within 24 hours and significantly reduce the sequencing cost down to US$600 per human genome. Based on its proprietary technology and perpetual drive for innovation MGI is the only Chinese company among the three clinical genetic sequencer producers in the world, bringing the power of choice and new applications to genomics markets all over the world. There are over 1200 MGI sequencers installed in 22 countries worldwide to date.